Biogen
BIIB
1,103 hedge funds and large institutions have $51.4B invested in Biogen in 2018 Q1 according to their latest regulatory filings, with 95 funds opening new positions, 423 increasing their positions, 419 reducing their positions, and 101 closing their positions.
1% more repeat investments, than reductions
Existing positions increased: 423 | Existing positions reduced: 419
0.46% less ownership
Funds ownership: 89.15% → 88.69% (-0.46%)
6% less first-time investments, than exits
New positions opened: 95 | Existing positions closed: 101
2% less funds holding
Funds holding: 1,123 → 1,103 (-20)
7% less funds holding in top 10
Funds holding in top 10: 28 → 26 (-2)
14% less capital invested
Capital invested by funds: $60B → $51.4B (-$8.68B)
33% less call options, than puts
Call options by funds: $700M | Put options by funds: $1.05B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$700M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$340M |
| 3 |
Renaissance Technologies
New York
|
+$195M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$189M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$160M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.4B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$721M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$363M |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$231M |
| 5 |
State Street
Boston,
Massachusetts
|
-$229M |
BIIB Hedge Fund Activity: Q1 2018 in Review
1,103 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2018, worth a combined $51.4B — down 14% from $60B a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of BIIB and 95 opened new positions — a net loss of 6 holders — while 419 trimmed existing stakes and 423 added.
The largest buyer was Deutsche Bank, adding an estimated $700M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.4B.
- 1,103 institutional investors held Biogen (BIIB) as of Q1 2018, down from 1,123 in Q4 2017.
- Funds reported $51.4B of Biogen stock for Q1 2018, down 14% quarter-over-quarter.
- 95 funds opened new Biogen positions in Q1 2018 and 101 closed out, a net change of -6 holders.
- The largest Biogen buyer in Q1 2018 was Deutsche Bank, an estimated $700M added.
- The largest Biogen seller in Q1 2018 was T. Rowe Price Associates, an estimated $1.4B sold.
Based on aggregated 13F filings for Q1 2018.